Loading clinical trials...
Loading clinical trials...
A Multicenter Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Patients With Refractory or Relapsed Hodgkin's Lymphoma (HL)
Conditions
Interventions
Oxaliplatin-based chemotherapy (ESHAOx)
Locations
1
South Korea
National Cancer Center, Korea
Goyang, South Korea
Start Date
February 1, 2011
Primary Completion Date
June 1, 2013
Completion Date
December 1, 2013
Last Updated
February 21, 2011
NCT06667687
NCT05618925
NCT05623982
NCT03314974
NCT06014073
NCT04586478
Lead Sponsor
National Cancer Center, Korea
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions